Medincell S.A (MEDCL) | Stock Overview & Key Data
Medincell S.A. | Mid-cap | Healthcare
Medincell S.A. | Mid-cap | Healthcare
Medincell S.A Performance Comparison
Stock Range
Today's Range
Low: €15.95
High: €16.17
on August 8, 2025
52 Week Range
Low: €12.00
High: €19.00
on April 7, 2025
on September 4, 2024
All-Time High: €20.00 on April 6, 2020
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Market Cap
€524.6M
EPS
-0.62
P/E Ratio (TTM)
N/A
Forward P/E
78.50
P/B Ratio
N/A
PEG Ratio
78.50
Div. Yield
N/A
ROE
112.65%
Beta
1.075
Debt to Equity
-3.59
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-17.30%
Profit Margin
-66.50%
Returns and Earnings
Return on Assets (TTM)
-20.38%
Return on Equity (TTM)
112.65%
EBITDA
€-9.9M
Net Income (TTM)
€-18.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.84
Quarterly Revenue Growth (YoY)
385.80%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Medincell S.A MEDCL | 524.62M Mid-cap | -6.41% | -1.79% | 2.65% | 0.70% | -9.29% | -0.06% | 197.92% | 112.23% |
| Abivax SA ABVX | 4.49B Large-cap | -5.31% | 791.18% | 913.38% | 961.30% | 732.42% | 474.95% | 572.59% | 214.97% |
| Valneva SE VLA | 546.93M Mid-cap | 9.79% | 50.21% | 22.53% | 14.70% | 55.41% | 11.58% | -65.68% | -34.65% |
| BNP Paribas Easy BLUE | 463.10M Mid-cap | -2.20% | -0.89% | 0.52% | -5.19% | -5.19% | -2.63% | 1.50% | 49.76% |
| Inventiva S.A IVA | 391.52M Mid-cap | 0.70% | 8.71% | -10.87% | 23.18% | 36.02% | 32.41% | -46.04% | -71.29% |
| Nanobiotix NANO | 283.01M Mid-cap | -1.63% | 44.95% | 97.06% | 55.81% | 96.42% | 35.01% | 44.96% | -15.35% |
Ownership & Short Interest
Insider Ownership
39.10%
Institutional Ownership
30.43%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
113K
Average 90-Day Volume
77K
Medincell S.A Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Medincell S.A would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is MEDCL's 52-week high and low?
- In the last 52 weeks, Medincell S.A reached a high of €19.00 (on September 4, 2024) and a low of €12.00 (on April 7, 2025).
- What is the market cap and P/E ratio for MEDCL?
- Curious about Medincell S.A's size and valuation? Its market capitalization stands at 524.62M. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is 78.50.
- Does MEDCL pay dividends? If so, what's the yield?
- As for dividends, Medincell S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Medincell S.A's main competitors or similar companies to consider before investing?
When looking at Medincell S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abivax SA
ABVX4.49B Healthcare Biotechnology 474.95% 572.59% Valneva SE
VLA546.93M Healthcare Biotechnology 11.58% -65.68% BNP Paribas Easy
BLUE463.10M Healthcare Biotechnology -2.63% 1.50% Inventiva S.A
IVA391.52M Healthcare Biotechnology 32.41% -46.04% Nanobiotix
NANO283.01M Healthcare Biotechnology 35.01% 44.96% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Medincell S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Medincell S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 112.65%, the Debt to Equity ratio from the most recent quarter is -3.59, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for MEDCL?
- Looking at Medincell S.A's growth, its revenue over the trailing twelve months (TTM) was €28M. Compared to the same quarter last year (YoY), quarterly revenue grew by 385.80%, and quarterly earnings saw a YoY growth of N/A.
- How much of MEDCL stock is held by insiders and institutions?
- Wondering who owns Medincell S.A stock? Company insiders (like executives and directors) hold about 39.10% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 30.43%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.